Hello all,
I read over on melanomainternational.org that the FDA has published June 3 as the announcememt date (I hope I'm getting this right–hopefully Tim can clarify) for decisions on both of GSK's drug submissions–the BRAF inhibitor and the MEK inhibitor. I'm not sure if that's a firm date or not–again, maybe Tim knows.
Hello all,
I read over on melanomainternational.org that the FDA has published June 3 as the announcememt date (I hope I'm getting this right–hopefully Tim can clarify) for decisions on both of GSK's drug submissions–the BRAF inhibitor and the MEK inhibitor. I'm not sure if that's a firm date or not–again, maybe Tim knows.
The drugs were submitted separately as monotherapies, so I guess there's the possibility that one could be approved and not the other, although it seems that both will be approved. The fact that they will have separate approvals begs some questions, such as: what happens if someone stops responding to Zelboraf…will the MEK inhibitor be added to the Zel, or would the person be prescribed both drugs? When someone first begins the BRAF drugs, will we be able to receive uniform insurance coverage for both, or will it be an insurance company-by insurance company decision?
You can hop on over to the site and look at the entire post…I didn't know if it would be permitted to cut and paste it here.
Karen
